Bath Savings Trust Co Has $687,000 Position in Novo Nordisk A/S (NYSE:NVO)

Bath Savings Trust Co decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,984 shares of the company’s stock after selling 915 shares during the period. Bath Savings Trust Co’s holdings in Novo Nordisk A/S were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Novare Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC grew its position in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares during the last quarter. Benjamin Edwards Inc. raised its stake in Novo Nordisk A/S by 2.6% during the second quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after acquiring an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton boosted its stake in shares of Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after purchasing an additional 94 shares in the last quarter. Finally, Burns J W & Co. Inc. NY increased its position in Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after purchasing an additional 100 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Trading Down 2.3 %

Shares of NVO traded down $1.92 during trading hours on Tuesday, hitting $83.11. 5,653,913 shares of the stock were exchanged, compared to its average volume of 6,128,639. The firm has a market capitalization of $372.96 billion, a P/E ratio of 26.90, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The business has a 50-day moving average of $102.51 and a 200-day moving average of $120.68.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.